Novo Nordisk Earnings Beat but Study Data, Wegovy Pill Sales Underwhelm

Dow Jones13:53

0553 GMT - Novo Nordisk's second quarter and guidance upgrade are clearly better than expected, but investors seem focused on disappointing study data and weight-loss pill sales, Sydbank's Soren Lontoft Hansen says. Novo Nordisk delivered positive growth rates and sent a very positive signal in terms of exchanging lower prices for increased volume, he says. "In our opinion, this should immediately give rise to a sigh of relief among investors." However, shares fell 6% in the U.S. and Sydbank says possible explanations include disappointing data for its developmental CagriSema drug compared to Eli Lilly's Mounjaro. "It puts a spotlight on the Novo Nordisk pipeline and its robustness." Also, although the Wegovy pill is booming, sales are slightly lower than expected, and the company also booked a major 6 billion Danish kroner noncash impairment charge.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment